Eli Lilly v. Humanwell Pharmaceutical: REYVOW® Lasmiditan Patent Dispute Dismissed
Eli Lilly and CoLucid Pharmaceuticals filed suit in New Jersey against Humanwell Pharmaceutical US and Epic Pharma over US11053214B2, the patent underlying REYVOW® (lasmiditan) migraine tablets. All claims were dismissed without prejudice by joint stipulation under Rule 41(a)(1)(A)(ii) — with no costs awarded to either side — just 201 days after filing.
Lilly’s REYVOW® patent suit ends in no-fault dismissal after 201 days
On 21 March 2025, Eli Lilly & Company and CoLucid Pharmaceuticals, Inc. filed an infringement action in the U.S. District Court for the District of New Jersey against Humanwell Pharmaceutical US, Inc. and Epic Pharma, LLC. The suit centred on US11053214B2, a patent covering lasmiditan — the active ingredient in REYVOW® tablets at the 50 mg and 100 mg dosage strengths — a next-generation, non-vasoconstricting acute migraine treatment that works via selective 5-HT1F receptor agonism.
The case closed on 8 October 2025, just 201 days after filing, via a joint stipulation of dismissal under Federal Rule of Civil Procedure 41(a)(1)(A)(ii). All claims, counterclaims, and affirmative defences were dismissed without prejudice, with no costs or attorneys’ fees awarded to either party. The without-prejudice designation means Lilly and CoLucid are not precluded from reasserting infringement claims against either Humanwell or Epic Pharma if circumstances change — for example, if an ANDA approval proceeds or a new filing triggers a fresh 30-month stay.
The 201-day resolution timeline is notably swift for ANDA-style pharmaceutical patent litigation, which typically involves extended expert discovery and claim construction proceedings. The public record does not disclose whether the parties reached a settlement agreement, licensing terms, or simply agreed to stand down — a common dynamic when a generic applicant adjusts its filing strategy or when commercial negotiations are ongoing. The retention of district court jurisdiction to enforce the dismissal suggests the parties may have entered into an underlying agreement not publicly filed.
Filing to Case Dismissed in 201 days
201 days from filing to dismissal — faster than the median ANDA patent case in New Jersey
Dismissed without prejudice: what the stipulation means for both parties
Rule 41(a)(1)(A)(ii): dismissal by stipulation, not by the court
A Rule 41(a)(1)(A)(ii) dismissal is a voluntary, jointly signed stipulation — it requires no court order and takes effect upon filing. Critically, because this dismissal is without prejudice, it carries no res judicata effect. Lilly and CoLucid are not barred from re-filing substantially identical claims. The court retains jurisdiction solely to enforce any related agreements, suggesting a background settlement framework may exist.
No merits adjudicationLilly preserves US11053214B2 — no validity finding, full right to refile
A without-prejudice dismissal is strategically favourable for the patent holder: US11053214B2 exits the litigation with its validity and enforceability entirely intact. No court has ruled on claim construction, obviousness, or infringement. Lilly and CoLucid retain the ability to assert the patent against Humanwell or Epic Pharma again — or against any other generic filer — without the dismissal being used as a prior adjudication.
Patent validity preservedHumanwell and Epic Pharma face no injunction — but no clearance either
The defendants secured a dismissal without facing a permanent injunction or damages award, which limits their immediate exposure. However, the without-prejudice nature means they have obtained zero legal clearance on their ANDA product. If either party proceeds toward commercial launch of a lasmiditan generic, Lilly could promptly refile and seek a new 30-month stay, depending on ANDA status and regulatory timelines. The lack of a validity ruling leaves the patent risk unresolved.
No patent clearance obtainedREYVOW® exclusivity window remains commercially intact for Lilly
Lasmiditan is the only FDA-approved 5-HT1F receptor agonist for acute migraine and is non-vasoconstricting — differentiating it from triptans. With US11053214B2 unchallenged on the merits, Lilly’s exclusivity position in this segment is commercially undisturbed for now. Generic entry risk is deferred, not eliminated. Sector participants developing ditan-class or migraine CNS therapies should monitor Humanwell’s and Epic Pharma’s ANDA status for signals of renewed litigation activity.
Generic entry deferredFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Eli Lilly & Company | Company | Pharmaceutical innovator — holder of US11053214B2 covering lasmiditan (REYVOW®)Search in Eureka ↗ |
| Defendant | HUMANWELL PHARMACEUTICAL US, INC. | Company | Generic pharmaceutical manufacturer and ANDA applicant targeting REYVOW® lasmiditan tabletsSearch in Eureka ↗ |
| Plaintiff counsel | Christine Intromasso Gannon | Attorney | Counsel for Eli Lilly & CompanySearch in Eureka ↗ |
| Plaintiff counsel | Liza M. Walsh | Attorney | Counsel for Eli Lilly & CompanySearch in Eureka ↗ |
| Plaintiff counsel | Patrick Steven Salamea | Attorney | Counsel for Eli Lilly & CompanySearch in Eureka ↗ |
| Plaintiff law firm | Walsh Pizzi O’Reilly Falanga LLP | Law Firm | Representing Eli Lilly & CompanySearch in Eureka ↗ |
| Defendant counsel | HYUN YOON | Attorney | Counsel for HUMANWELL PHARMACEUTICAL US, INC.Search in Eureka ↗ |
| Defendant law firm | Polsinelli PC | Law Firm | Representing HUMANWELL PHARMACEUTICAL US, INC.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulation is precise in its scope: it dismisses ‘all claims, counterclaims, and affirmative defences’ — leaving no pending matter before the court on the merits. The without-prejudice designation, combined with the court’s retained jurisdiction, is a dual signal: there is no estoppel effect, and a private enforcement mechanism likely exists. Neither party obtained a judicial determination on infringement or validity, meaning US11053214B2 remains both enforceable and commercially unresolved.
US11053214B2 — Lasmiditan selective 5-HT1F receptor agonist for acute migraine
US11053214B2 covers lasmiditan, the active pharmaceutical ingredient in REYVOW® tablets at 50 mg and 100 mg dosages. Lasmiditan is a highly selective serotonin 1F receptor agonist — structurally and mechanistically distinct from triptans in that it does not cause vasoconstriction, making it suitable for patients with cardiovascular risk factors. The patent, filed under application number US16/467208, protects the compound and formulation at the core of Lilly’s acute migraine franchise.
For the branded migraine space, US11053214B2 represents a high-value exclusivity asset: REYVOW® is the only approved ditan-class therapy for acute migraine in the U.S., and the patent has never been challenged to a merits ruling. Any generic or 505(b)(2) filer in the lasmiditan space must contend with this patent. The compound’s non-vasoconstricting profile gives it a differentiated label, strengthening the commercial logic of defending exclusivity aggressively. The patent’s unadjudicated status means its claim scope remains untested in litigation.
Should you run an FTO against US11053214B2 before filing a lasmiditan ANDA?
Any pharmaceutical team developing a generic lasmiditan tablet, a lasmiditan-containing combination product, or a structurally adjacent 5-HT1F receptor agonist should treat US11053214B2 as a primary FTO hurdle. This patent has never been subjected to claim construction, IPR, or a validity ruling — meaning its enforceable scope is broader and less predictable than patents that have survived litigation scrutiny. ANDA filers, 505(b)(2) applicants, and NDA holders in the ditan class should assess clearance before any FDA submission.
PatSnap Eureka’s FTO Search Agent can map the full claim landscape of US11053214B2, identify the prosecution history, locate any related family members, and surface prior art that has not yet been tested in litigation. For R&D teams, Eureka can also identify white-space opportunities in the 5-HT1F agonist space and flag whether any of your own compound libraries present freedom-to-operate risks. Start with a targeted patent landscape search to understand Lilly and CoLucid’s full lasmiditan IP portfolio before your next ANDA filing decision.
Run a freedom-to-operate analysis on US11053214B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA patent cases: lasmiditan & acute migraine formulation disputes
Cases in the District of New Jersey involving branded migraine therapy patents and ANDA-triggered infringement actions provide the closest strategic comparators to this Lilly lasmiditan dispute.
What this case signals for the branded migraine therapy IP landscape
A without-prejudice dismissal on a first-wave ANDA challenge to REYVOW® leaves Lilly’s IP position intact but unresolved — a pattern worth tracking.
Without-prejudice dismissals preserve the litigation option — monitor ANDA pipelines
When a branded pharma company dismisses without prejudice this early, it often signals a background licensing or standstill agreement rather than a clear win for either side. Teams monitoring the lasmiditan generic pipeline should track FDA’s Orange Book and ANDA approval status for Humanwell and Epic Pharma to anticipate when Lilly might refile.
US11053214B2 has never been adjudicated — validity remains an open question
No court has ruled on claim construction or validity for US11053214B2. For any company developing a lasmiditan formulation or a structurally adjacent 5-HT1F agonist, this patent represents unlitigated risk. A freedom-to-operate analysis against this patent is prudent before any generic ANDA filing or biosimilar-adjacent development programme in this class.
Eli v HUMANWELL — key questions answered
The patent at issue is US11053214B2, covering lasmiditan — the active ingredient in REYVOW® (lasmiditan) tablets 50 mg and 100 mg. The case was filed in the District of New Jersey on 21 March 2025 by Eli Lilly and CoLucid Pharmaceuticals against Humanwell Pharmaceutical US and Epic Pharma.
The case was dismissed pursuant to a joint stipulation under Rule 41(a)(1)(A)(ii), agreed by all parties. The public record does not disclose the reason — this type of stipulation is commonly associated with confidential settlement or licensing negotiations. The without-prejudice designation means no merits ruling was made and Lilly retains the right to refile.
No. A dismissal without prejudice carries no validity or infringement ruling. US11053214B2 exits this litigation with its legal presumption of validity fully intact. No claim construction, obviousness analysis, or infringement determination was made by the New Jersey district court in this proceeding.
Yes. Because the dismissal was without prejudice, Lilly and CoLucid are not barred from reasserting US11053214B2 against Humanwell Pharmaceutical US or Epic Pharma in future proceedings. The stipulation also retains district court jurisdiction to enforce any related agreements, which may affect the timing and conditions of any future refile.
Plaintiffs are Eli Lilly & Company and CoLucid Pharmaceuticals, Inc. Defendants are Humanwell Pharmaceutical US, Inc. and Epic Pharma, LLC. Plaintiff counsel included Walsh Pizzi O’Reilly Falanga LLP; defendant counsel was Polsinelli PC. The case was heard in the U.S. District Court for the District of New Jersey.
PatSnap Eureka searches patents and litigation data to answer instantly.